Biomerieux 

$86.11
124
-$0.77-0.89% Friday 17:59

Statistics

Day High
80.66
Day Low
80.66
52W High
138.15
52W Low
77
Volume
66
Avg. Volume
192
Mkt Cap
10.19B
P/E Ratio
21.78
Dividend Yield
1.32%
Dividend
1.13

Upcoming

Dividends

1.32%Dividend Yield
Jun 26
$1.13
Jun 25
$1.04
Jun 24
$0.91
Jun 23
$0.92
Jun 22
$0.91
10Y Growth
11.65%
5Y Growth
8.49%
3Y Growth
7.36%
1Y Growth
9.49%

Earnings

28JulExpected
Q4 2023
Q1 2024
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Q2 2026
0
0.73
1.46
2.19
Expected EPS
2.03600289676
Actual EPS
1.99588461308

Financials

9.95%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
4.69BRevenue
467.26MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BMXMF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Thermo Fisher Scientific
TMO
Mkt Cap226.94B
Thermo Fisher Scientific offers a broad range of analytical instruments and reagents, directly competing in the diagnostics and research sectors similar to Biomerieux.
Danaher
DHR
Mkt Cap145.98B
Danaher Corporation, through its subsidiaries like Cepheid, competes in the life sciences and diagnostics market, offering products that overlap with Biomerieux's offerings.
Bio-Rad Laboratories
BIO
Mkt Cap10.32B
Bio-Rad Laboratories provides a variety of products for the life science research and clinical diagnostics markets, making it a direct competitor in several areas of Biomerieux's business.
Resmed
RMD
Mkt Cap32.94B
ResMed Inc. is known for its products in the health sector, including diagnostics, where it competes with Biomerieux in certain niches.
Becton Dickinson
BDX
Mkt Cap50.32B
Becton, Dickinson and Company operates in the healthcare and diagnostics industries, offering products and services that compete with Biomerieux's diagnostics solutions.
Qiagen NV
QGEN
Mkt Cap8.98B
Qiagen N.V. offers technologies and products for preanalytical sample preparation and diagnostics, competing in the molecular diagnostics market alongside Biomerieux.
Abbott Laboratories
ABT
Mkt Cap187.45B
Abbott Laboratories has a broad range of healthcare products including diagnostics, competing with Biomerieux especially in the areas of infectious disease testing.
Agilent Technologies
A
Mkt Cap42.53B
Agilent Technologies provides analytical instruments, services, and consumables in the life sciences, diagnostics, and applied chemical markets, competing with Biomerieux in laboratory diagnostics.
Guardant Health
GH
Mkt Cap21.66B
Guardant Health operates in the precision oncology field, offering liquid biopsy tests that compete with Biomerieux's molecular diagnostics solutions in the oncology segment.

About

bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL, a rapid AST system; ETEST, a gradient method on culture media; BIOMERIEUX EPISEQ CS, a whole genome sequencing solution for epidemiologic monitoring; VIDAS, a specific marker of severe bacterial infections/sepsis; and Biomérieux vision suite, a software that provides information to support diagnosis and clinical decision making. It also provides culture media and associated instruments; ARGENE that provides PCR tests for diagnosing viral respiratory diseases; EMAG system and NUCLISENS extraction reagents for DNA and RNA extraction; GENE-UP and VERIFLOW for detection of microorganisms for the food industry; ETEST for manual measurement of minimum inhibitory concentration of an antibiotic; API and RAPIDEC CARBA NP for identification of bacteria and manual antimicrobial susceptibility testing; BIOBALL for quantitative microbiological quality control; CHEMUNEX, a microbiology instrument; ENDONEXT for detection of endotoxins; TEMPO for fluorescence counting of bacteria; and Hybiome, a CLIA technology, as well as lab consultancy service and training modules. The company was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. operates as a subsidiary of Institut Mérieux SA.
Show more...
CEO
Pierre Boulud
Employees
15078
Country
France
ISIN
FR0013280286
WKN
000A2DXZH

Listings

0 Comments

Share your thoughts

FAQ

What is Biomerieux stock price today?
The current price of BMXMF is $86.11 USD — it has decreased by -0.89% in the past 24 hours. Watch Biomerieux stock price performance more closely on the chart.
What is Biomerieux stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Biomerieux stocks are traded under the ticker BMXMF.
Is Biomerieux stock price growing?
BMXMF stock has fallen by -1.93% compared to the previous week, the month change is a +6.75% rise, over the last year Biomerieux has showed a -35.86% decrease.
What is Biomerieux market cap?
Today Biomerieux has the market capitalization of 10.19B
When is the next Biomerieux earnings date?
Biomerieux is going to release the next earnings report on March 04, 2027.
What were Biomerieux earnings last quarter?
BMXMF earnings for the last quarter are 2.27 USD per share, whereas the estimation was 2.32 USD resulting in a -1.97% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Biomerieux revenue for the last year?
Biomerieux revenue for the last year amounts to 4.69B USD.
What is Biomerieux net income for the last year?
BMXMF net income for the last year is 467.26M USD.
Does Biomerieux pay dividends?
Yes, BMXMF dividends are paid annual. The last dividend per share was 1.13 USD. As of today, Dividend Yield (FWD)% is 1.32%.
How many employees does Biomerieux have?
As of September 08, 2026, the company has 15,078 employees.
In which sector is Biomerieux located?
Biomerieux operates in the Health & Wellness sector.
When did Biomerieux complete a stock split?
The last stock split for Biomerieux was on September 21, 2017 with a ratio of 3:1.
Where is Biomerieux headquartered?
Biomerieux is headquartered in Marcy l'Étoile, France.